KOREA study (Korea Osimertinib Real world Evidence study to Assess safety and efficacy)

Trial Identifier:	D5160R00009
Sponsor:	AstraZeneca
NCTID::	NCT02777567
Start Date:	September 2016
Primary Completion Date:	March 2020
Study Completion Date:	March 2020
Condition:	Lung Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Stay informed about new Trial Results Summaries with our email notification service

Trial Locations

Country	Location
South Korea, South Korea	South Korea, South Korea

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.